← Back to Analyst Consensus 
BMRN Buy
BIOMARIN PHARMACEUTICAL INC
Current Price —
Implied Upside —
Analysts 35
30-Day Momentum
▲ 0 upgrades / ▼ 0 downgrades / 4 reiterations from 4 firms
Next Earnings
Nov 3, 2026 (8 days)
Rating Timeline
| Date ▼ | Firm | Action | From → To Rating | Price Target | Firm Rating |
|---|---|---|---|---|---|
| Oct 21, 2026 | Morgan Stanley | maintain | Overweight → Overweight | — | 54% |
| Oct 20, 2026 | JP Morgan | maintain | Overweight → Overweight | — | 55% |
| Oct 20, 2026 | Cantor Fitzgerald | reiterate | Overweight → Overweight | — | 50% |
| Oct 14, 2026 | Barclays | maintain | Overweight → Overweight | — | 53% |
| Sep 10, 2026 | HC Wainwright & Co. | reiterate | Neutral → Neutral | — | 44% |
| Sep 1, 2026 | Piper Sandler | maintain | Overweight → Overweight | — | 54% |
| Aug 31, 2026 | Jefferies | maintain | Buy → Buy | — | 52% |
| Aug 31, 2026 | HC Wainwright & Co. | maintain | Neutral → Neutral | — | 44% |
| Aug 19, 2026 | BMO Capital | initiate | Outperform → Outperform | — | 53% |
| Aug 18, 2026 | HC Wainwright & Co. | maintain | Neutral → Neutral | — | 44% |
| Aug 17, 2026 | Piper Sandler | maintain | Overweight → Overweight | — | 54% |
| Aug 17, 2026 | Barclays | maintain | Overweight → Overweight | — | 53% |
| Aug 10, 2026 | Canaccord Genuity | maintain | Buy → Buy | — | 48% |
| Aug 7, 2026 | Morgan Stanley | maintain | Overweight → Overweight | — | 54% |
| Aug 7, 2026 | Oppenheimer | maintain | Outperform → Outperform | — | 52% |
| Aug 7, 2026 | HC Wainwright & Co. | maintain | Neutral → Neutral | — | 44% |
| Jul 16, 2026 | Citigroup | maintain | Buy → Buy | — | 54% |
| Jul 7, 2026 | RBC Capital | maintain | Sector Perform → Sector Perform | — | 55% |
| May 22, 2026 | Canaccord Genuity | maintain | Buy → Buy | — | 48% |
| May 19, 2026 | B of A Securities | maintain | Buy → Buy | — | 53% |
| May 19, 2026 | Citigroup | initiate | — → Buy | — | 54% |
| May 18, 2026 | HC Wainwright & Co. | maintain | Neutral → Neutral | — | 44% |
| May 7, 2026 | Canaccord Genuity | maintain | Buy → Buy | — | 48% |
| May 5, 2026 | Bernstein | maintain | Outperform → Outperform | — | 52% |
| May 5, 2026 | Morgan Stanley | maintain | Overweight → Overweight | — | 54% |
| May 5, 2026 | RBC Capital | reiterate | Sector Perform → Sector Perform | — | 55% |
| May 5, 2026 | Evercore ISI Group | maintain | Outperform → Outperform | — | 58% |
| May 5, 2026 | HC Wainwright & Co. | reiterate | Neutral → Neutral | — | 44% |
| Mar 11, 2026 | B of A Securities | maintain | Buy → Buy | — | 53% |
| Mar 4, 2026 | Barclays | maintain | Overweight → Overweight | — | 53% |
| Mar 2, 2026 | HC Wainwright & Co. | reiterate | Neutral → Neutral | — | 44% |
| Mar 2, 2026 | Freedom Broker | maintain | Buy → Buy | — | 59% |
| Feb 26, 2026 | Canaccord Genuity | maintain | Buy → Buy | $104 | 48% |
| Feb 25, 2026 | Bernstein | maintain | Outperform → Outperform | $94 | 52% |
| Feb 25, 2026 | Guggenheim | maintain | Buy → Buy | $86 | 52% |
| Feb 25, 2026 | HC Wainwright & Co. | maintain | Neutral → Neutral | $55 | 44% |
| Feb 24, 2026 | Oppenheimer | maintain | Outperform → Outperform | $95 | 52% |
| Feb 18, 2026 | Wells Fargo | maintain | Overweight → Overweight | $75 | 54% |
| Feb 6, 2026 | Piper Sandler | maintain | Overweight → Overweight | $84 | 54% |
| Jan 20, 2026 | Canaccord Genuity | upgrade | Hold → Buy | $98 | 48% |
| Dec 23, 2025 | Truist Securities | maintain | Buy → Buy | $100 | 54% |
| Dec 22, 2025 | HC Wainwright & Co. | maintain | Neutral → Neutral | $60 | 44% |
| Dec 3, 2025 | Leerink Partners | downgrade | Outperform → Market Perform | $60 | 51% |
| Nov 6, 2025 | Stifel | downgrade | Buy → Hold | $61 | 53% |
| Nov 3, 2025 | Freedom Broker | maintain | Buy → Buy | — | 59% |
| Nov 3, 2025 | Bernstein | maintain | Outperform → Outperform | $88 | 52% |
| Oct 28, 2025 | Truist Securities | maintain | Buy → Buy | $80 | 54% |
| Oct 28, 2025 | Wells Fargo | maintain | Overweight → Overweight | $70 | 54% |
| Oct 28, 2025 | Stifel | maintain | Buy → Buy | $73 | 53% |
| Oct 28, 2025 | Barclays | maintain | Overweight → Overweight | $80 | 53% |
Price Target Trend
Jul 12, 2026 Latest: $91.56 Oct 25, 2026
EPS Estimates
+1y $6.39
Lo: $4.14 Hi: $7.35
12 analysts ▲2
0q $-0.12
Lo: $-0.48 Hi: $0.24
14 analysts +1q $1.69
Lo: $1.52 Hi: $1.89
11 analysts ▲1
0y $3.51
Lo: $3.37 Hi: $3.79
14 analysts Cross-Platform Signals
No cross-platform signals in the last 90 days